Press Releases

Date Title
11 Jun 2024 Illumina DRAGEN v4.3 powers most comprehensive, accurate genome with industry-leading innovations
4 Jun 2024 Illumina launches latest chemistry across most popular mid-throughput sequencers, enabling higher quality and greater speed for customers at lower cost
3 Jun 2024 Illumina Board of Directors approves spin-off of GRAIL; declares spin-off dividend of GRAIL shares
3 Jun 2024 Illumina appoints Everett Cunningham Chief Commercial Officer
29 May 2024 Illumina drives genomic testing as standard of care in oncology through collaborative research presented at ASCO
28 May 2024 Illumina releases 2023 Corporate Social Responsibility Report
20 May 2024 Anna Richo joins Illumina's Board of Directors
15 May 2024 Illumina To Webcast Upcoming Investor Conference
6 May 2024 Illumina publicly files Form 10 registration statement ahead of planned divestiture of GRAIL
3 May 2024 Illumina To Webcast Upcoming Investor Conference
2 May 2024 Illumina Reports Financial Results for First Quarter of Fiscal Year 2024
12 Apr 2024 Illumina's planned divestment of GRAIL approved by the European Commission
9 Apr 2024 Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer
4 Apr 2024 Illumina to Announce First Quarter 2024 Financial Results on Thursday, May 2, 2024
8 Feb 2024 Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2023
9 Jan 2024 Illumina Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2023
5 Jan 2024 Illumina expands collaboration with Janssen to advance molecular residual disease cancer test
4 Jan 2024 Illumina to Announce Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 8, 2024
4 Jan 2024 The Alliance for Genomic Discovery welcomes Bristol Myers Squibb, GSK, and Novo Nordisk